CureVac (NASDAQ:CVAC – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare CureVac to related businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, earnings, valuation and dividends.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for CureVac and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
| CureVac Competitors | 9829 | 15119 | 45431 | 1586 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 102.62%. Given CureVac’s peers stronger consensus rating and higher possible upside, analysts clearly believe CureVac has less favorable growth aspects than its peers.
Risk & Volatility
CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, CureVac’s peers have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.
Valuation & Earnings
This table compares CureVac and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CureVac | $70.74 million | $175.50 million | 6.47 |
| CureVac Competitors | $705.29 million | $10.71 million | -15.00 |
CureVac’s peers have higher revenue, but lower earnings than CureVac. CureVac is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares CureVac and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CureVac | 199.92% | -23.03% | -19.09% |
| CureVac Competitors | -12,357.18% | -197.96% | -30.56% |
Insider and Institutional Ownership
17.3% of CureVac shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 2.1% of CureVac shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
CureVac peers beat CureVac on 7 of the 13 factors compared.
CureVac Company Profile
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
